拱东医疗(605369) - 2024 Q4 - 年度业绩预告

Financial Performance - The company expects a net profit of approximately 175 million yuan for the year 2024, an increase of about 65.37 million yuan or 60.37% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be around 173.24 million yuan, reflecting an increase of approximately 65.58 million yuan or 60.91% year-on-year[2] - The previous year's net profit attributable to shareholders was 109.13 million yuan, with a net profit after deducting non-recurring gains and losses of 107.66 million yuan[5] Business Strategy - The company has focused on custom business for overseas major clients, leading to increased revenue and improved gross margin[5] - The company has implemented cost control measures and lean management, resulting in a decrease in expense ratio compared to the previous year[5] Subsidiary Performance - The operating performance of the U.S. subsidiary Trademark Plastics Inc. has shown significant improvement compared to the previous year[5] Non-Operating Gains - Non-operating gains and losses, including government subsidies and financial asset disposals, are expected to be around 1.76 million yuan, an increase of approximately 29,520 yuan compared to the previous year[5] Accounting and Forecasting - The company has not identified any significant accounting treatment impacts on the current performance forecast[6] - There are no major uncertainties affecting the accuracy of this performance forecast[7] - The forecast data is preliminary and subject to change, with final figures to be disclosed in the official 2024 annual report[8]